$20.27
0.34% yesterday
Nasdaq, Nov 20, 10:03 pm CET
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Stock price

$20.27
+2.53 14.26% 1M
+9.23 83.61% 6M
+8.44 71.34% YTD
+8.78 76.41% 1Y
+15.44 319.67% 3Y
+10.35 104.33% 5Y
+10.35 104.33% 10Y
+10.35 104.33% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.07 0.34%
ISIN
BMG762791017
Symbol
ROIV
Industry

Key metrics

Basic
Market capitalization
$14.1b
Enterprise Value
$9.8b
Net debt
positive
Cash
$4.4b
Shares outstanding
689.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
695.8 | 599.8
EV/Sales
480.1 | 413.9
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.7%
ROCE
-23.3%
ROIC
-181.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.3m | $23.6m
EBITDA
$-1.1b | $-1.2b
EBIT
$-1.2b | $-1.1b
Net Income
$-374.0m | $-1.0b
Free Cash Flow
$-784.4m
Growth (TTM | estimate)
Revenue
-74.1% | -18.8%
EBITDA
-5.2% | -8.9%
EBIT
-3.8% | -2.3%
Net Income
-107.8% | -483.2%
Free Cash Flow
-0.4%
Margin (TTM | estimate)
Gross
96.4%
EBITDA
-5,628.1% | -5,075.4%
EBIT
-5,659.4%
Net
-1,839.6% | -4,252.8%
Free Cash Flow
-3,858.5%
More
EPS
$-0.5
FCF per Share
$-1.1
Short interest
4.8%
Employees
750
Rev per Employee
$40.0k
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Roivant Sciences forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Roivant Sciences forecast:

Buy
89%
Hold
11%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
20 20
74% 74%
100%
- Direct Costs 0.73 0.73
91% 91%
4%
20 20
72% 72%
96%
- Selling and Administrative Expenses 566 566
16% 16%
2,783%
- Research and Development Expense 604 604
19% 19%
2,973%
-1,144 -1,144
5% 5%
-5,628%
- Depreciation and Amortization 6.37 6.37
69% 69%
31%
EBIT (Operating Income) EBIT -1,151 -1,151
4% 4%
-5,659%
Net Profit -374 -374
108% 108%
-1,839%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
Seeking Alpha
2 days ago
Roivant Sciences Ltd. ( ROIV ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good afternoon.
Positive
Seeking Alpha
7 days ago
ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1...
Neutral
Seeking Alpha
9 days ago
Roivant Sciences Ltd. ( ROIV ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST Company Participants Richard Pulik - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 750
Founded 2014
Website roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today